tbuckley/cabot-search huggingface dataset:
P2.02-014 Perioperative Outcomes and Downstaging Following Neoadjuvant Therapy For Lung Cancer – Analysis of the National Cancer Database
Authors: Scott Atay, Jiangong Niu, Sharon Giordano, Mara Antonoff, John Heymach, Wayne Hofstetter, Reza Mehran, David Rice, Jack Roth, Ara Vaporciyan, Garrett Walsh, William William, Stephen Swisher, Boris Sepesi
Journal: Journal of Thoracic Oncology (2017)
OA 07.02 Characteristics of Lung Cancer Cell-Free Tumor DNA (CfDNA) Shedding and Correlation with Tumor Burden as Measured by RECIST
Authors: V. Lam, L. Li, J. Wang, H. Tran, W. Rinsurongkawong, R. Lanman, J. Lewis, J. Roth, S. Swisher, V. Papadimitrakopoulou, J. Lee, J. Zhang, J. Heymach
Journal: Journal of Thoracic Oncology (2017)
OA 14.06 Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
Authors: M. Ahn, B.C. Cho, S. Siena, A. Drilon, F. De Braud, M. Krebs, T. John, C. Karapetis, A. Johnson, E. Chow-Maneval, P. Multani, R. Doebele
Journal: Journal of Thoracic Oncology (2017)
ACTR-53. SAFETY AND EFFICACY EVALUATION OF A PHASE II STUDY OF BORTEZOMIB IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
Authors: Xiao-Tang Kong, Nhung Nguyen, Yoon Choi, Guicheng Zhang, Huytram Nguyen, Emese Filka, Stacy Green, William Yong, Linda Liau, Tania Kaprealian, Whitney Pope, Phioanh Nghiemphu, Timothy Cloughesy, Andrew Lassman, Albert Lai
Journal: Neuro-Oncology (2017)

Optune therapy with tumor treatment fields (TTFields) is approved for the treatment of recurrent glioblastoma due to a recent clinical trial that showed better quality of life and comparable overall survival to conventional therapy. In the newly diagnosed setting, the addition of TTFields to standard therapy consisting of surgery, radiation and temozolomide has also been shown to prolong tumor progression and improve overall survival. TTFields are low-intensity, alternating frequency electric fields that have been shown to disrupt cell division and subsequently tumor growth. Apoptosis and cell cycle arrest have been seen in vitro, and shown in mice and rabbit tumor models. Though preclinical studies are ongoing, glioblastoma patients who have undergone TTFields therapy have not yet been assessed at autopsy to determine both the pathological signature of TTFields therapy, and the pattern of failure. Whole brain samples were acquired and analyzed pathologically from two recurrent GBM patients at autopsy. One patient served as a control and one considered a test patient who had undergone TTFields therapy. Tissue samples were acquired from regions suspicious of tumor and treatment effects. Samples were paraffin embedded and hematoxylin and eosin (H&E) stained, and pathologically reviewed by a board certified pathologist. Samples were then compared. The patient who underwent TTFields therapy showed regions of necrosis and increased cellular debris compared to the control patient who had pseudo-palisading and radiation necrosis. These findings suggest there is increased apoptosis in patients treated with TTFields compared to those on chemoradiation alone. Recruitment is ongoing for expansion of this study to include 10 patients treated with TTFields at recurrence and 10 at treated at initial diagnosis. Patients will be recruited from brain donation. Pathology will be compared to control patients naïve of TTFields therapy.
IMMU-09. DISRUPTION OF THE CCL2-CCR2 AXIS AUGMENTS THE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS TO SLOW PROGRESSION OF GLIOMAS
Authors: Adithya Gopinath, Defang Luo, Matthew Sarkisian, James Campbell, Israel Charo, Thomas Schall, Jeffrey Harrison
Journal: Neuro-Oncology (2017)

Therapeutic approaches that target the immune system in cancer are gaining traction, with agents that disrupt the PD-L1/PD-1 axis showing success in melanoma and lung cancers. Pre-clinical and early clinical studies also indicate that these immune checkpoint inhibitors have efficacy in glioblastoma. While excitement exists for these approaches, identifying pharmacological targets that contribute to the immunosuppressive tumor microenvironment is certain to lead to adjunctive therapies that will enhance the efficacy of existing immune-based therapies. Immune suppressive myeloid lineage-derived cells within the tumor microenvironment are a major contributor to the inability of the immune system to mount an effective anti-tumor response. The migration and function of myeloid cells are controlled by chemokines and their cognate receptors, with the CCL2/CCR2 chemokine system being a major pathway utilized by myeloid-derived cells to gain access into tissues. To determine if chemokine receptor CCR2 contributes to tumor progression in pre-clinical mouse models of glioma. The impact of either CCR2 deficiency or a CCR2 antagonist (CCX598) in combination with PD-L1:PD-1 axis inhibitors on the overall survival of glioma-bearing mice was assessed in two murine glioma models (GL261 and KR158). Anti-PD-1 treatment was more effective at slowing progression of GL261 and KR158 gliomas in mice lacking both copies of CCR2. A reduced presence of CCR2+/CD11b+ cells within GL261 and KR158 gliomas established in CCR2-deficient mice was also evident. The CCR2 antagonist, CCX598, augmented the effects of either anti-PD-L1 or anti-PD-1 treatment to slow glioma progression, but had no effect on GL261 tumor-bearing mice when delivered as a monotherapy. Genetic deficiency or pharmacological antagonism of CCR2 augments the effects of immune checkpoint inhibitors to slow glioma progression. These pre-clinical results support combining CCR2 antagonists with immune checkpoint inhibitors for the treatment of glioblastoma patients.
MA 11.03 Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405)
Authors: J. Wang, Y. Cheng, Y. Wu, T. An, H. Gao, K. Wang, Q. Zhou, Y. Hu, Y. Song, C. Ding, F. Peng, L. Liang, Y. Hu, C. Huang, C. Zhou, Y. Shi, L. Zhang, X. Ye, Y. Sun
Journal: Journal of Thoracic Oncology (2017)
U2AF1 Mutations in S34 and Q157 Create Distinct Molecular and Clinical Contexts
Authors: Vera Adema, Cassandra M. Hirsch, Bartlomiej P Przychodzen, Aziz Nazha, Teodora Kuzmanovic, Eiju Negoro, Dewen You, Hideki Makishima, Michael J. Clemente, Hetty E. Carraway, Mikkael A. Sekeres, Valeria Visconte, Jaroslaw P. Maciejewski
Journal: Blood (2016)
IMMU-28. DEFINING MOLECULAR MECHANISMS OF RESISTANCE TO GLIOBLASTOMA (GBM) IMMUNITY USING A NOVEL CRISPR/CAS9 IN VIVO LOSS-OF-FUNCTION SCREENING PLATFORM
Authors: Martha R Neagu, Maria Carmela Speranza, Robert T Manguso, Sean E Lawler, Gordon J Freeman, John Doench, Arlene H Sharpe, W Nicholas Haining
Journal: Neuro-Oncology (2017)

Developing a high-throughput, in vivo, loss-of-function screening platform for GBM immune-escape mechanisms and identifying novel immuno-therapy targets. While recent success of cancer immunotherapy asserts the importance of immune-mediated tumor eradication, patients respond heterogeneously. Expanding the clinical utility of immunotherapy requires a rational method for identifying new combination therapies and resistance mechanisms. These mechanisms can be discovered using high-throughput functional genetic screens and we have adapted a novel loss-of-function in vivo screen to identify mechanisms of immune-evasion in the CNS. B16-melanoma or CT2A- and GL261-astrocytoma cells bearing Cas9-endonuclease were engineered to express a library of barcoded guide RNAs. These cells form tumors when implanted in the flank (B16) or intracranially (CT2A, GL261) in immunocompetent animals. Tumor-bearing animals were subjected to immunotherapy with vaccination or PD-1 checkpoint blockade. Barcode-relative representation was measured by next-generation sequencing at the time of tumor implantation and tumor harvest post-immunotherapy. Here we report an in vivo, pooled, loss-of-function genetic screen using Cas9/CRISPR genome editing in mouse transplantable tumors treated with vaccination and PD-1 checkpoint blockade. Screening 2,400 genes expressed by melanoma cells for those that synergize with or cause resistance to checkpoint blockade recovered known immune-evasion molecules PD-L1 and CD47. Novel immunotherapy targets validated individually, identifying essential pathways of immune-evasion. When recapitulating this approach in the CNS, 500-1000 genes can be functionally screened under immune-pressure. We are currently screening a GBM-specific library based on differential in vitro gene expression in the tumor cytokine-environment in an in vivo pooled loss-of-function genetic screen using graded immune-pressure to identify novel immunotherapy targets in GBM. Our screening assay provides the first high-throughput method for systematically identifying resistance mechanisms and new candidate targets for immunotherapy in CNS tumors and can screen multiple immunotherapy combinations, serving as an important tool for the identification of next-generation combination immunotherapies.
MA 11.02 Circulating Tumor DNA in Early Stage NSCLC: High Sensitivity Analysis in Low Burden Disease. LUCID Study Update
Authors: A. Ruiz-Valdepenas, K. Heider, G. Doughton, W. Qian, C. Massie, D. Chandrananda, C. Smith, D. Gale, E. Moseley, C. Castedo, A. Stone, C. Thorbinson, T. Eisen, D. Rassl, S. Harden, R. Rintoul, N. Rosenfeld
Journal: Journal of Thoracic Oncology (2017)
Age-related trends in utilization and outcome of autologous haematopoietic cell transplantation for multiple myeloma.
Authors: Holger W Auner, Richard Szydlo, Jennifer Hoek, Hartmut Goldschmidt, Didier Blaise, Gareth J Morgan, Philippe Moreau, Michel Attal, Noel Jean Milpied, Nigel Russell, Mats Brune, Gordon Cook, Pieter Sonneveld, Stefan Schoenland, Laurent Garderet, Nicolaus Kroeger
Journal: Journal of Clinical Oncology (2014)

8592 Background: Autologous haematopoietic cell transplantation (AHCT) is considered a standard of care in eligible patients with multiple myeloma (MM) aged <65 years but is not generally recommended in patients ≥65 years of age. We analysed all first AHCTs that were reported to the EBMT 1991-2010 to study trends in utilisation and outcome of AHCT for the treatment of MM in relation to age. Methods: A total of 53675 patients from 31 European countries and 497 centres were included in the analysis. Patients were grouped into six age groups (<40, 40-49, 50-59, 60-64, 65-69, ≥70 years) and four calendar periods (1991-1995, 1996-2000, 2001-2005, and 2006-2010) by age at, and year of, first AHCT. Results: Median age at AHCT increased from 52.8 years in 1991-1995 to 59 years in 2006-2010 (p<.001). The number of patients undergoing AHCT increased throughout all four calendar periods for all age groups. The highest proportional increase was observed for patients aged 65-69 and ≥70 years. While the number of tandem AHCTs decreased in 2006-2010 in all age groups, patients aged ≥70 years showed the smallest decrease and had the highest rate of tandem transplants in this calendar period (19%). Two-year survival rates increased for all age groups since 1991-1995. The greatest improvement was observed in patients aged 65-69 years (from 55.3% in 1991-1995 to 82.9% in 2006-2010). The smallest improvement in 2-year survival was seen in patients aged <40 years (from 82.2% in 1991-1995 to 85.9% in 2006-2010). Consequently, the maximum difference in 2-year survival between age groups decreased from 27.9% in 1991-1995 to 5.7% in 2006-2010. Five-year survival was higher in 2006-2010 compared to 1991-1995 in all age groups. However, we observed an emerging trend of decreasing 5-year survival for patients aged <40 and 40-49 years in the most recent calendar period. Conclusions: The data demonstrate that utilisation of AHCT for MM continued to increase in recent calendar periods, particularly in patients aged ≥65 years. The data also show that post-transplant survival improved considerably more in older than in younger patients. Thus, AHCT is a commonly used treatment strategy with good outcome in MM patients aged ≥ 65 years.
P1.07-032 28-Color, 30 Parameter Flow Cytometry to Dissect the Complex Heterogeneity of Tumor Infiltrating T Cells in Lung Cancer
Authors: J. Brummelman, F. De Paoli, A. Anselmo, P. Novellis, G. Veronesi, M. Alloisio, E. Lugli
Journal: Journal of Thoracic Oncology (2017)
P3.13-007 A Feasible Follow-Up Program Using FDG-PET/CT for Asymptomatic Postoperative Non-Small-Cell Lung Cancer Patients
Authors: H. Toba, N. Kawakita, T. Sawada, M. Tsuboi, H. Takizawa, K. Kondo
Journal: Journal of Thoracic Oncology (2017)
IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients
Authors: Weili Wang, Lei Huang, Jian-Yue Jin, Shruti Jolly, Yong Zang, Huanmei Wu, Li Yan, Wenhu Pi, Lang Li, Andrew L. Mellor, Feng-Ming (Spring) Kong
Journal: Cancer Research (2017)

Host immunity influences the impact of radiotherapy (RT) in cancer, but mechanistic connections remain obscure. In this study, we investigated the relationship of indoleamine 2,3-dioxygenase (IDO) systemic activity on clinical outcomes in RT-treated non-small cell lung cancer (NSCLC). IDO-mediated production of kynurenine and the kynurenine:tryptophan ratio in patient blood serum were determined for stage III NSCLC patients at times before, during, and after RT administration and then correlated to overall survival (OS), progression-free survival, and disease progression rate in patients. We found the impact of RT on these serum IDO markers to be heterogeneous in patients. On average, kynurenine:tryptophan ratios were reduced during RT but restored after RT. Notably, both baseline levels of kynurenine:tryptophan and changes in the levels of kynurenine after RT were significantly associated with OS. When combined, favorable change and favorable baseline corresponded with very long-term OS (median OS was not reached after 57 months of median follow-up). Favorable change combined with unfavorable baseline still corresponded with a lack of distant metastases. Our results suggest that RT alters IDO-mediated immune status in NSCLC patients and that changes in this serum biomarker may be useful to predict outcomes and perhaps personalize RT dosage to improve survival.Significance: Radiotherapy appears to influence systemic IDO activity and to exert a significant impact on metastatic risk and overall survival, with possible implications for defining a biomarker to optimize radiation dose in patients to improve outcomes. Cancer Res; 78(3); 809-16. ©2017 AACR.
Clinical outcomes of estrogen receptor (ER)-negative and progesterone receptor (PgR)-positive invasive breast cancer.
Authors: Melissa Chan, Martin Chang, Rosa Gonzalez, Belinda Lategan, Elvira del Barco, Francisco Emilio Vera-Badillo, Paula Quesada, Robyn Goldstein, Ignacio Cruz, Alberto Ocana, Juan J. Cruz, Eitan Amir
Journal: Journal of Clinical Oncology (2014)

567 Background: Hormone receptor (HR) expression has prognostic and predictive significance in breast cancer. Most HR-positive tumors are ER positive (ER+). In contrast, tumors that are ER negative (ER-) and PgR positive (PgR+) are uncommon and may represent an analytic artifact. We have previously shown that ER-/PgR+ tumors have been associated with younger age, higher grade, and Her2/neu over-expression suggesting a distinct biologic entity (Proceedings 103rdUSCAP Meeting). Here we evaluated clinical outcomes of ER-/PgR+ breast cancers. Methods: We retrospectively reviewed a well-characterized database comprising 816 sequential patients diagnosed with early stage invasive breast carcinoma in Salamanca, Spain. Outcomes of interest were time to relapse (TTR) and overall survival (OS). Multivariable Cox proportional hazards analysis was conducted to assess the association of ER-/PgR+ with TTR and OS in comparison to ER+ and to ER- and PgR negative (ER-/PgR-) tumors. Results: Fifty-six patients (7%) had ER-/PgR+, 624 (77%) had ER+ and 136 (17%) had ER-/PgR- phenotypes. For ER-/PgR+, ER+ and ER-/PgR- tumors, five-year relapse rates were 36%, 20% and 42%, and five-year OS was 92%, 93% and 66%, respectively. ER-/PgR+ showed annual hazards of relapse that were intermediate between ER+ and ER-/PgR- patients. Relapses occurred early in follow-up for ER-/PgR+ and ER-/PgR- tumors with few relapses beyond year 6. ER+ tumors showed a continuous risk of relapse throughout follow-up. Multivariable analysis for TTR is shown in the Table. Only nodal status and receptor group were associated with worse OS. Conclusions: ER-/PgR+ tumors are a rare, but defined subgroup. They have a higher risk of relapse than ER+ tumors, but lower than ER-/PgR- tumors. The timing of relapse more closely resembles ER-/PgR- disease, whereas overall survival more closely resembles ER+ disease. Further research on the role of PgR in breast carcinogenesis is warranted. Variable Hazard ratio 95% CI p Age at diagnosis 0.97 0.96-0.98 <0.001 Tumor size 1.13 1.04-1.23 0.006 Nodal metastases 2.22 1.49-3.33 <0.001 Grade 1.36 1.00-1.85 0.048 Receptor group ER+ ER-/PgR+ ER-/PgR- - Ref 1.57 3.64 - Ref 0.79-3.12 1.69-7.82 - Ref 0.20 0.001
P1.16-010 Development of a Novel Surgical Marking Method Using Low Power Laser Light
Authors: K. Ohtani, S. Maehara, K. Imai, H. Furumoto, M. Hagiwara, T. Okano, M. Kakihana, N. Kajiwara, T. Ohira, N. Ikeda
Journal: Journal of Thoracic Oncology (2017)
P2.02-042 Clinical Significance of the Tumor Expression of PD-L1 Using Four Immunohistochemistry Assays in Non-Small Cell Lung Cancer. Multicentre Study
Authors: C. Ortiz –Villalón, A. Yoshikawa, L. Kis, A. Montero, A. Roden, H.H.n. Pham, C. Fernandez, J. Fukuoka, R. Lewensohn, L. De Petris
Journal: Journal of Thoracic Oncology (2017)
Cluster epidemico di malattia dei legionari: Parigi, Giugno 1998
Authors: B Decludt, L Guillotin, B van Gastel, A Perrocheau, L Capek, M Ledrans, J Etienne, D Carlier, S Jarraud, S Dubrou, M Reyrolle
Journal: Eurosurveillance (1999)

Dal 29 Giugno al Luglio 1998, il sistema di notifica obbligatoria (declaration obligatoire - DO) e l'European Surveillance Scheme for Travel Associated Legionnaires’ disease, gestito dall'European Working Group for Legionella Infections (EWGLI), hanno notificato al Reseau National de Sante Publique (RNSP) quattro casi di malattia dei legionari in cittadini britannici. Uno dei casi e stato scoperto dal sistema di sorveglianza, reso piu efficiente in occasione del Campionato Mondiale di Calcio. Tutti i quattro casi avevano soggiornato a Parigi nei dieci giorni precedenti alla manifestazione dei sintomi. E' stata condotta un'indagine per confermare l'esistenza di un focolaio, per identificare un'origine comune di contaminazione e per adattare le misure di controllo alla specifica situazione epidemiologica.
Validation and comparison of the molecular classifications of pancreatic carcinomas
Authors: David J. Birnbaum, Pascal Finetti, Daniel Birnbaum, Emilie Mamessier, François Bertucci
Journal: Molecular Cancer (2017)

Four molecular classifications of pancreatic ductal adenocarcinoma (PDAC), biologically and clinically relevant and based on gene expression profiles, were established in the recent years, including the Collisson's, Moffitt's ("tumor" and "stroma" classifications), and Bailey's classifications. The aim of this study was to validate the prognostic value of the Moffitt's classifications and to compare the Collisson's, Moffitt's, and Bailey's classifications in a large series of samples. We collected clinical and gene expression data of PDAC samples from 15 public data sets, resulting in a total of 846 primary cancer samples, including 601 with survival annotation. All samples were classified according to each of the four multigene classifiers. We confirmed the independent prognostic value of the Moffitt "tumor", Moffitt "stroma", and Bailey's classifications, but not that of the Collisson's classification. Despite a relatively low gene overlap, all classifications were associated with pathological grade, an important prognostic feature and reflect of intrinsic molecular characteristics of tumors. The concordance rate in term of "good-prognosis" vs. "poor-prognosis" prediction by classifiers was relatively high (from 73 to 86%) between the three "tumor" classifications based on tumor gene lists (Collisson, Moffitt "tumor", Bailey), but low (from 50 to 60%) with the Moffitt's stroma classification based on stroma genes. Multivariate analysis incorporating the four classifiers together retained as significant variables the Moffitt "stroma" and Bailey classifications, highlighting the complementarity of classifiers based on tumor epithelium (Bailey) and tumor stroma (Moffitt stroma). Our results reinforce the clinical validity of subtyping in PDAC, which should be regarded as a collection of separate diseases. Beside their clinical utility that remains to be demonstrated, the clinical interest of the subtypes, notably those from Bailey's and Moffitt's "stroma" classifiers that show independent prognostic value, will be reinforced by the identification of new biomarkers and/or therapeutic targets in each subtype for designing and testing novel specific targeted therapies.
Pediatric Exclusivity and Regulatory Authority
Authors: Jeanie Kim, Joseph S. Ross, Amy Kapczynski
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P3.16-046 Pneumonectomy After Induction/Neoadjuvant Treatment for NSCLC: Morbidity, Mortality and Long-Term Survival
Authors: C. Gebitekin, A. Toker, W. Weder, H. Melek, B. Özkan, I. Opitz, G. Cetinkaya, S. Collaud, A. Bayram
Journal: Journal of Thoracic Oncology (2017)
P3.01-084 Analysis on ALTER0303 Trial: aCECs Level May Correlate with Metastases Burden and Predict PFS of Anlotinib in Advanced NSCLC
Authors: Z. Liu, J. Wang, Z. Meng, X. Wang, C. Zhang, J. Chen, X. Jiang, L. Wang, L. Lin, X. Zhang, P. Chen, C. Huang, R. Jiang, K. Li
Journal: Journal of Thoracic Oncology (2017)
Trichinellosi associata a maiale: nascita di una nuova modalità di trasmissione?
Authors: J C Desenclos
Journal: Eurosurveillance (1999)

In questo numero, Eurosurveillance pubblica un rapporto su due epidemie di trichinellosi - costituite rispettivamente da otto e 42 casi - verificatesi nella regione tedesca di Rhine-Westfalia settentrionale tra l'Ottobre e il Dicembre 1998. Indagini epidemiologiche ben condotte hanno identificato il veicolo di trasmissione: carne macinata di maiale distribuita da un unico supermercato, nell'epidemia minore, e, nell'altra, salsicce crude affumicate prodotte da un'unica ditta.